Join to view full profile
2650 N Tenaya WaySte 201Las Vegas, NV 89128
Phone+1 702-735-7154
Dr. Madani is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Ali Madani is an oncologist based in Tucson, AZ, specializing in breast cancer, hematologic oncology, and thoracic cancer. He completed his fellowship in Hematology and Medical Oncology at Indiana University School of Medicine after a residency in Internal Medicine at Sparrow Hospital/Michigan State University. Dr. Madani holds a Ph.D. in Molecular Biology of Cancer and a Master's in Biostatistics from the University of Paris, and he graduated from Univer Algiers- Fac Med in 1988. He currently works as an investigator at Arizona Oncology/US Oncology, and has past experience as a physician at Hematology & Oncology Associates of Southern Michigan. His areas of expertise include amyloidosis, neutropenic fever, and myelodysplasia. Dr. Madani has authored several highly cited publications in the fields of digital medicine and oncology. His accolades include the Meaningful Use Stage 1 Certification and a Merit Award from ASCO.
Education & Training
Indiana University School of MedicineFellowship, Hematology and Medical Oncology, 2000 - 2003
University of Michigan Health - Sparrow/Michigan State UniversityResidency, Internal Medicine, 1997 - 2000- University of Paris VIIPhD, Molecular Biology of Cancer, 1993 - 1996
- University of ParisPh.D., Molecular Biology of Cancer, 1993 - 1996
- University of ParisMaster's, Biostatistics, 1993 - 1994
Certifications & Licensure
CA State Medical License 2020 - 2028
TX State Medical License 2023 - 2028
MI State Medical License 2000 - 2028
HI State Medical License 2020 - 2028
IN State Medical License 2000 - 2027
CO State Medical License 2020 - 2027
NM State Medical License 2023 - 2027
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
National Board of Physicians and Surgeons Hematology- National Board of Physicians and Surgeons Internal Medicine
- National Board of Physicians and Surgeons Medical Oncology
- Join now to see all
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification iKnowMed EHR, McKesson, 2012, 2014-2017
- CMS Meaningful Use Stage 1 Certification iKnowMed™ EHR, US Oncology, 2012, 2014-2017
- CMS Meaningful Use Stage 1 Certification iKnowMed EHR, McKesson, 2012, 2014-2017
Publications & Presentations
PubMed
- 3 citationsThe Comparison of Resistance Index of Testicular Artery Using Color Doppler Ultrasound in Infertile Men Undergoing Varicocelectomy.Amir Reza Dalili, Ali Madani, Saeid Sadeghi Joni
Journal of Reproduction & Infertility. 2021-04-01 - 456 citationsDeep learning-enabled medical computer vision.Andre Esteva, Katherine Chou, Serena Yeung, Nikhil Naik, Ali Madani
NPJ Digital Medicine. 2021-01-08 - 166 citationsDeep learning-enabled breast cancer hormonal receptor status determination from base-level H&E stainsNikhil Naik, Ali Madani, Andre Esteva, Nitish Shirish Keskar, Michael F. Press
Nature Communications. 2020-11-16
Journal Articles
- Phase II study of Imatinib Mesylate in chemotherapy refractory Germ Cell Tumors expressing KITEinhorn L, Brames M, Heinrich M, Corless C, American Journal of Clinical Oncology, 1/1/2006
- Expression of KIT and Epidermal Growth factor (EGFR) in Chemotherapy Refractory Non-Seminomatous Germ Cell TumorsKemmer K, Corless C, Ulbright T, Heinrich M, Einhorn L, Annals of Oncology, 1/1/2003
- New perspective in non-transplant strategies for chronic myelogenous leukemiaMadani A, Fellow Reporter, 1/1/2001
Abstracts/Posters
- Phase II study of Epirubicin plus Cisplatin in refractory germ cell tumorsMadani A, Annual meeting of the American Society of Clinical Oncology, Orlando, FL, 1/1/2003
- Expression of KIT and Epidermal Growth Factor receptor EGFR in chemotherapy-refractory germ cell tumorsMadani A, Annual meeting of the American Society of Clinical Oncology, Orlando, FL, 1/1/2002
- Expression of P13- MTCP1 is restricted to T-cell Prolymphocytic LeukemiaMadani A, Euro Cancer Conference, Paris, France, 1/1/1995
Press Mentions
Glendale Radiation Oncology Center Adds DoctorAugust 13th, 2021
Deep Learning-Enabled Medical Computer VisionJanuary 8th, 2021- Generative A.I. Arrives in the Gene Editing World of CRISPRApril 25th, 2024
Professional Memberships
- Member
- Member
Other Languages
- Arabic, French
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: